Molecule Information

General Information of the Molecule (ID: Mol04463)

• Name: BQ323636.1 ,Homo sapiens
• Synonyms: BQ323636.1
• Molecule Type: splice variant

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Anastrozole

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Disease Class: Breast adenocarcinoma [ICD-11: 2C60.1] [1]

• Resistant Disease: Breast adenocarcinoma [ICD-11: 2C60.1]
• Resistant Drug: Anastrozole
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: AR signalling pathway; Regulation; N.A.
• In Vitro Model: MCF-7 BQ cells; Breast; Homo sapiens (Human); N.A.
• In Vitro Model: ZR-75 BQ cells; Breast; Homo sapiens (Human); N.A.
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: Mechanistic study indicates that BQ overexpression enhances androgen receptor (AR) activity and in the presence of anastrozole, causes hyper-activation of AR signalling, which unexpectedly enhanced cell proliferation, through increased expression of?CDK2,?CDK4, and?CCNE1. BQ overexpression reverses the effect of anastrozole in ER+ve breast cancer in an AR-dependent manner, whilst co-treatment with the AR antagonist bicalutamide recovered its therapeutic effect both?in vitro?and?in vivo. Thus, for BQ-overexpressing breast cancer, targeting AR can combat anastrozole resistance.

References

• Ref 1: Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer. J Pathol. 2023 Oct;261(2):156-168.